Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models.

Autor: Papaevangelou E; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, Guy's Hospital, London, United Kingdom.; Institute of Medical and Biomedical Education, St. George's University of London, London, United Kingdom., Esteves AM; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, Guy's Hospital, London, United Kingdom., Dasgupta P; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, Guy's Hospital, London, United Kingdom.; Urology Centre, Guy's Hospital, London, United Kingdom., Galustian C; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, Guy's Hospital, London, United Kingdom.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Jul 03; Vol. 14, pp. 1196829. Date of Electronic Publication: 2023 Jul 03 (Print Publication: 2023).

Prostate cancer cells enhance interleukin-15-mediated expansion of NK cells.

Autor: Sakellariou C; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Kings College London, Guys Hospital, London, UK., Elhage O; Urology Centre, Guys Hospital, London, UK., Papaevangelou E; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Kings College London, Guys Hospital, London, UK., Giustarini G; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Kings College London, Guys Hospital, London, UK., Esteves AM; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Kings College London, Guys Hospital, London, UK., Smolarek D; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Kings College London, Guys Hospital, London, UK., Smith RA; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Kings College London, Guys Hospital, London, UK., Dasgupta P; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Kings College London, Guys Hospital, London, UK.; Urology Centre, Guys Hospital, London, UK., Galustian C; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Kings College London, Guys Hospital, London, UK.

Publikováno v: BJU international [BJU Int] 2020 Jan; Vol. 125 (1), pp. 89-102. Date of Electronic Publication: 2019 Aug 07.

Cytotopic (Cyto-) IL-15 as a New Immunotherapy for Prostate Cancer: Recombinant Production in Escherichia coli and Purification.

Autor: Esteves AM; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, Guy's Hospital, London, United Kingdom., Papaevangelou E; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, Guy's Hospital, London, United Kingdom., Smolarek D; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, Guy's Hospital, London, United Kingdom., Dasgupta P; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, Guy's Hospital, London, United Kingdom.; Urology Centre, Guy's Hospital, London, United Kingdom., Galustian C; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, Guy's Hospital, London, United Kingdom.

Publikováno v: Frontiers in molecular biosciences [Front Mol Biosci] 2021 Oct 27; Vol. 8, pp. 755764. Date of Electronic Publication: 2021 Oct 27 (Print Publication: 2021).

Meis1 restrains the growth and epithelial-mesenchymal transition of breast cancer cells through the HOXB13/PI3K/AKT signaling pathway.

Autor: Wanqiong Zheng¹ zwq5171717@163.com, Ye Tian², Yiming Zhang¹, Binnan Li¹

Publikováno v: European Journal of Gynaecological Oncology. Dec2024, Vol. 45 Issue 6, p117-123. 7p.

A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant.

Autor: LeBlanc, Richard^1,2,3 (AUTHOR) richard.leblanc.1@umontreal.ca, Thiant, Stéphanie² (AUTHOR), Terra, Rafik^1,3 (AUTHOR) rterra.hmr@ssss.gouv.qc.ca, Ahmad, Imran^1,2,3 (AUTHOR) imran.ahmad.1@umontreal.ca, Claveau, Jean-Sébastien^1,2,3 (AUTHOR) js.delisle@umontreal.ca, Bambace, Nadia^1,2,3 (AUTHOR) silvy.lachance@umontreal.ca, Bernard, Léa^1,2,3 (AUTHOR) thomas.kiss@umontreal.ca, Cohen, Sandra^1,2,3 (AUTHOR) denis-claude.roy@umontreal.ca, Delisle, Jean-Sébastien^1,2,3 (AUTHOR) guy.sauvageau@umontreal.ca, Lachance, Silvy^1,2,3 (AUTHOR), Kiss, Thomas^1,2,3 (AUTHOR), Roy, Denis-Claude^1,2,3 (AUTHOR), Sauvageau, Guy^1,3 (AUTHOR), Roy, Jean^1,2,3 (AUTHOR) jean.roy.1@umontreal.ca

Publikováno v: Current Oncology. Nov2024, Vol. 31 Issue 11, p7258-7274. 17p.